Europe

Servier’s $2.65B Muscular Dystrophy Deal Turns Rare Neurology Into a Commercial Priority

Physical activity continues to strengthen its case as a cross-disease prevention strategy

Can cortisol become the next target in type 2 diabetes?

Alpha Radioligand Therapy Moves Prostate Cancer Into a New Infrastructure Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
